GlycoEra AG is a Swiss-American clinical-stage biotech building a new class of precision medicines that selectively degrade the circulating proteins driving autoimmune disease. Spun out of LimmaTech Biologics in 2021 and powered by a proprietary glycoengineering platform, the company designs bifunctional biologics (G-LyTACs) that pull pathogenic autoantibodies out of the bloodstream with speed and depth - without the broad immune suppression of existing therapies. Its lead program, GE8820, targets pathogenic IgG4 autoantibodies. Backed by $179M across Series A and an oversubscribed $130M Series B, GlycoEra operates from Wädenswil, Switzerland and Newton, Massachusetts.
Ganesh Kaundinya is President and CEO of GlycoEra, a Swiss-US biotech building extracellular protein degraders to treat autoimmune disease. An MIT-trained chemical engineer, he co-founded Momenta Pharmaceuticals and helped grow it from a sugar-sequencing concept into a public company with FDA-approved products, later acquired by Johnson & Johnson for $6.5 billion. At GlycoEra he raised an oversubscribed $130 million Series B in 2025 to push a precision IgG4 degrader toward the clinic.